We are live on ! Find out more
ANTH

Anthera Pharmaceuticals, Inc.
ANTH

Delisted

ANTH was delisted on the 27th of June, 2018.

72 hedge funds and large institutions have $10.8M invested in Anthera Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 19

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

0% more funds holding

Funds holding: 7272 (0)

45% less call options, than puts

Call options by funds: $91K | Put options by funds: $164K

84% less capital invested

Capital invested by funds: $67M → $10.8M (-$56.2M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
72
Holders Change
Holders Change %
0%
% of All Funds
1.8%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
13
Increased
25
Reduced
19
Closed
11
Calls
$91K
Puts
$164K
Net Calls
-$73K
Net Calls Change
-$309K
Name Holding Trade Value Shares
Change
Change in
Stake
Franklin Resources
1
Franklin Resources
California
$2.08M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$1.19M -$3.41M -197,015 -46%
A
3
Abingworth
United Kingdom
$1.17M +$757K +43,710 +68%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.17M +$533K +30,772 +16%
BFA
5
BlackRock Fund Advisors
California
$820K -$857K -49,498 -24%
BIT
6
BlackRock Institutional Trust
California
$563K
State Street
7
State Street
Massachusetts
$445K -$49.6K -2,866 -3%
Northern Trust
8
Northern Trust
Illinois
$273K +$5.94K +343 +0.7%
RSCM
9
Rock Springs Capital Management
Maryland
$247K -$151K -8,750 -16%
Millennium Management
10
Millennium Management
New York
$247K +$782K +45,168 +1,911%
UBS Group
11
UBS Group
Switzerland
$222K +$286K +16,531 +63%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$197K +$57.4K +3,315 +9%
VKH
13
Virtu KCG Holdings
New York
$176K +$539K +31,133 +1,123%
Citadel Advisors
14
Citadel Advisors
Florida
$154K +$482K +27,854 +1,530%
RPAM
15
Rhenman & Partners Asset Management
Sweden
$130K -$216K -12,500 -33%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$129K -$50.9K -2,940 -11%
RFCA
17
R&F Capital Advisors
New York
$111K +$370K +21,401 New
ID
18
Integral Derivatives
New York
$109K +$365K +21,085 New
BIM
19
BlackRock Investment Management
Delaware
$100K +$2.09K +121 +0.6%
Morgan Stanley
20
Morgan Stanley
New York
$92K +$275K +15,911 +818%
TCIM
21
TIAA CREF Investment Management
New York
$82K -$11.6K -668 -4%
PAM
22
Panagora Asset Management
Massachusetts
$82K +$215K +12,445 +376%
DADC
23
D.A. Davidson & Co
Montana
$73K -$443K -25,615 -65%
CS
24
Credit Suisse
Switzerland
$73K +$203K +11,751 +484%
California Public Employees Retirement System
25
California Public Employees Retirement System
California
$66K

ANTH Hedge Fund Activity: Q4 2016 in Review

72 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q4 2016, worth a combined $10.8M — down 84% from $67M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new ANTH positions and 11 closed out — a net gain of 2 holders — while 25 added to existing stakes and 19 trimmed.

The largest buyer was Millennium Management, adding an estimated $782K. The largest seller was ProQuest Associates IV, exiting entirely with an estimated $5.99M sold.

  • 72 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $10.8M of Anthera Pharmaceuticals, Inc. stock for Q4 2016, down 84% quarter-over-quarter.
  • 13 funds opened new Anthera Pharmaceuticals, Inc. positions in Q4 2016 and 11 closed out, a net change of +2 holders.
  • The largest Anthera Pharmaceuticals, Inc. buyer in Q4 2016 was Millennium Management, an estimated $782K added.
  • The largest Anthera Pharmaceuticals, Inc. seller in Q4 2016 was ProQuest Associates IV, an estimated $5.99M sold.

Based on aggregated 13F filings for Q4 2016.